Literature DB >> 10903326

Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.

Y Ishigaki1, S Oikawa, T Suzuki, S Usui, K Magoori, D H Kim, H Suzuki, J Sasaki, H Sasano, M Okazaki, T Toyota, T Saito, T T Yamamoto.   

Abstract

Lipoprotein glomerulopathy (LPG) is a unique renal disease characterized by thrombus-like substances in markedly dilated glomerular capillaries, dysbetalipoproteinemia, and elevated plasma concentrations of apoE. Recent studies identified several apoE mutations in patients with LPG, including apoE2(R145P) Sendai (apoE-Sendai). Virus-mediated transduction of apoE-Sendai in apoE-deficient hypercholesterolemic mice resulted in insufficient correction of hypercholesterolemia and a marked and temporal induction of plasma triglyceride levels. In vitro binding studies showed that apoE-Sendai has a reduced affinity for the low density lipoprotein receptor, suggesting that dysbetalipoproteinemia in LPG is caused by the apoE mutation. Furthermore, histological examination revealed marked intraglomerular depositions of apoE-containing lipoproteins in mice injected with apoE-Sendai virus. These LPG-like depositions were detected 6 days after virus injection and were sustained for at least 60 days. Our results demonstrated that apoE-Sendai is an etiological cause of LPG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903326     DOI: 10.1074/jbc.M005906200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy.

Authors:  Yoshiro Miyahara; Shinsuke Nishimura; Maho Watanabe; Kenji Ito; Hitoshi Nakashima; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2011-11-11       Impact factor: 2.801

2.  Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Authors:  Ryosuke Usui; Masaki Takahashi; Kosaku Nitta; Minako Koike
Journal:  CEN Case Rep       Date:  2016-03-04

3.  The kidney and lipids: preface.

Authors:  Bertram Kasiske; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-04       Impact factor: 2.801

4.  Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Authors:  Hagai Tavori; Daping Fan; Ilaria Giunzioni; Lin Zhu; MacRae F Linton; Agnes B Fogo; Sergio Fazio
Journal:  J Lipid Res       Date:  2014-09-02       Impact factor: 5.922

Review 5.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

6.  Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.

Authors:  Atsunori Ishimura; Maho Watanabe; Hitoshi Nakashima; Kenji Ito; Katsuhisa Miyake; Shizue Mochizuki; Yasushi Ishigaki; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2009-05-21       Impact factor: 2.801

Review 7.  Topics in lipoprotein glomerulopathy: an overview.

Authors:  Takao Saito; Akira Matsunaga; Kenji Ito; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

Review 8.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

9.  Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy.

Authors:  Dimitra Georgiadou; Kostas Stamatakis; Eleni K Efthimiadou; George Kordas; Donald Gantz; Angeliki Chroni; Efstratios Stratikos
Journal:  J Lipid Res       Date:  2012-10-30       Impact factor: 5.922

10.  Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.

Authors:  Boxun Luo; Fengxian Huang; Qicai Liu; Xiaoyan Li; Wenfang Chen; Shu-Feng Zhou; Xueqing Yu
Journal:  Am J Nephrol       Date:  2007-11-29       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.